Endocrine disorders Flashcards
Diagnosing diabetes
Serum fasting glucose ≥ 126 on 2 occasions
A1c greater than 6.5-7
“impaired glucose tolerance”: fasting glucose 100-126
normal fasting glucose: 60-100
DM1- ketones in blood/urine
Managing DM1
Baseline labs: ketones, diagnostic markers, lipid panel, EKG, renal studies, peripheral pulses and neuro, eye/foot exams
Dietary teaching: total carb intake 55-60 percent of diet
Insulin for ketones: 0.5 units/kg/day, 2/3 dose in AM and 1/3 in PM
DM2: pathology, s/sx
- circulating insulin exists enough to prevent ketoacidosis but inadequate to meet patient’s insulin needs
- caused by either tissue insensitivity to insulin or insulin secretion defect
- S/sx: insidious onset, recurrent vaginitis, blurred vision, chronic skin infections, 3P’s (lesser extent than DM1)
Management of DM2
Obtain baseline: lipid panel, check for ketones, renal studies, EKG, peripheral pulses and neuro, eye/foot exam
Dietary teaching: carbs 55-60 percent of diet
Early oral antidiabetics: first choice is Metformin
Syndrome X
obesity, hypertension, abnormal lipids (low HDL, high triglycerides)
Metabolic syndrome
Expansion of “Syndrome X”; positive for 3 of the following:
- Waist circumference ≥ than 40 inches (102cm) in men, and ≥ 35 inches (89cm) in women
- BP ≥ 130/85
- triglycerides ≥ 150
- Fasting blood glucose ≥ 100
- HDL
Sulfonylureas
Stimulate pancreas to release more insulin
glipizide, glimepiride, glyburide
Biguanides
Metformin
standard of care for DM2
lactic acidosis is a potential side effect (presents with muscle pain)
alpha glucosidase inhibitors
less glucose absorbed by gut
acarbose (precose) and miglitol (glyset)
thiazolidinediones, or “glitazones”
rosiglitazone (avandia), pioglitazone (actos)
decrease gluconeogenesis
assoc. with possible HF or MI, therefore not widely used
non-sulfonylurea insulin release stimulators
repaglinide (Prandin)
nateglinide (Starlix)
Exenatide (Byetta)
injectable that mimics effects of incretins (signals pancreas to increase insulin secretion and stops gluconeogenesis)
may cause significant nausea, vomiting, diarrhea
Symlin (pramlintide)
injectable for DM1 and DM2
slows glucose absorption and inhibits action of glucagons
promotes weight loss while decreasing blood glucose levels
DD-4 inhibitor
Januvia (sitagliptin)
breaks down incretins (signal pancreas to increase insulin production, stops gluconeogenesis)
Somogyi effect
common in Type 1
low sugar at 3am, refractory increase in BG for morning fasting check
tx: lower evening/HS insulin